Decitabine

Catalog No.S1200 Synonyms: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Size Price Stock Quantity  
In DMSO USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 MVLGeY5kfGmxbjDBd5NigQ>? NHnDb5MxNjYEoN88US=> NEPTXVUzPCCq M3vnTJdifGW{ MnT3cY9lfWyjdHXzJJRp\SCpZX7lJIV5eHKnc4Ppc44hd2ZiTVHHSU1CKG2nbXLldpM> M2fIWVI2OTJ|MEiy
Eca109 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuwMlUwOi53L{Wg{txO NUTacpdCOjRxNEivO|IhcA>? Mmnve4F1\XJ? MUTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLTDk[ZBmdmSnboSgcYFvdmW{ M4nCS|I2OTJ|MEiy
Eca109 NWL6OGxKTnWwY4Tpc44hSXO|YYm= MYewMlXDqM7:TR?= MXi2M|EzNzJ2IHi= MX\3ZZRmeg>? MXXpcohq[mm2czDj[YxtKG2rZ4LheIlwdsLi NHL6PZYzPTF{M{C4Ni=>
Eca109 M3vOe2Z2dmO2aX;uJGF{e2G7 M2mwSlAvPcLizszN MUmyOEBp NXPFPHVZf2G2ZYK= MmfObY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MmjnNlUyOjNyOEK=
Eca109 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPk[VREOC53wrFOwG0> NWfhOG1qOjRiaB?= NEPqbox4[XSnch?= Mn;CbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MWqyOVEzOzB6Mh?=
Eca109 MmLOSpVv[3Srb36gRZN{[Xl? M{T3cFAvPS9zIN88US=> MXGyOEBp MUL3ZZRmeg>? MVPk[YNz\WG|ZYOg[ZhxemW|c3nvckBw\iCQRj5OvmIzKGGwZDDNUXAz MX:yOVEzOzB6Mh?=
SW1116  NVuyemVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMlUwOS9{L{Wg{txO M3roeVQ5KGh? M2fBeWROW09? MWjlcohidmOnczD0bIUhT2WoaYTpcoljKGmwZIXj[YQh[2WubDDpcohq[mm2aX;u Mkf6NlQ5PzR{OE[=
LOVO MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2KzN|AvPS9zL{KvOUDPxE1? MlnrOFghcA>? MYTEUXNQ MmKz[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> MWqyOFg4PDJ6Nh?=
SW1116  MXLGeY5kfGmxbjDBd5NigQ>? NY\jXYg{OTBizszN M{jIRlQ5KGh? M3H4OGROW09? M3W4PYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MorzNlQ5PzR{OE[=
LOVO Mnr0SpVv[3Srb36gRZN{[Xl? MlWzNVAh|ryP MnLEOFghcA>? NHTFVVBFVVOR M4nyU4lv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>? MWSyOFg4PDJ6Nh?=
SW1116  MYHBdI9xfG:|aYOgRZN{[Xl? MlHBNVAh|ryP NWG4SWpPPDhiaB?= NF\LeHhFVVOR MVHlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:|aYO= NV6xXmVzOjR6N{SyPFY>
LOVO NH7FfndCeG:ydH;zbZMhSXO|YYm= MW[xNEDPxE1? M134Z|Q5KGh? MVXEUXNQ M2niO4VvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=> M{\BSlI1QDd2Mki2
RPMI-8226 NXXYWYVGSXCxcITvd4l{KEG|c3H5 NXX5b3psOS9{IN88US=> MYe0PE84Oi97NjDo Ml71SG1UVw>? MoHKbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MY[yOFg{OzFyOB?=
OPM-2  Mn3ERZBweHSxc3nzJGF{e2G7 MoDWNU8zKM7:TR?= MnvKO|IwQTZxMUKwJIg> NFvDN3RFVVOR NWKzWnZbcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= M3GwflI1QDN|MUC4
JJN3  NU\mSFZ[SXCxcITvd4l{KEG|c3H5 NXHwWI8yOC53L{Gg{txO MWmyOE81QCCq MV;EUXNQ MmH5bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? M1rwNlI1QDN|MUC4
NCI-H929  NIHwUG9CeG:ydH;zbZMhSXO|YYm= Mk[4NU8zKM7:TR?= MlLsO|IwQTZxMUKwJIg> MULEUXNQ MX3pcoR2[2W|IHPlcIwh[XCxcITvd4l{ MlPONlQ5OzNzMEi=
RPMI-8226 NX[5ZlZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mni2NU8zKM7:TR?= MXKyOE81QC95MjDo Ml\USG1UVw>? M4HGSYFn\mWldIOgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCwZXfheIl3\Wy7 M2HVdFI1QDN|MUC4
OPM-2  NUDaXWY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDL[nlCOS9{IN88US=> M3m0eVI1NzR6L{eyJIg> MWLEUXNQ NXvEWG1i[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MmXINlQ5OzNzMEi=
JJN3  MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXVNE42NzFizszN MWmyOE81QC95MjDo Mor4SG1UVw>? NVrVOFY1[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MUiyOFg{OzFyOB?=
NCI-H929  NYKx[nhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYmxM|Ih|ryP M2DUXVI1NzR6L{eyJIg> NISzdXJFVVOR NUDLO5JV[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= NFjIO20zPDh|M{GwPC=>
HeLa M{n2fmtqdmG|ZTDBd5NigQ>? MoS5T4k:OTByMPMAl|UxODBizszNJIZweiCqRV7UNS=> MoXGNlQ4QDByOUi=
HeLa NYrIfmQyU2mwYYPlJGF{e2G7 Mk\kT4k:PS54INMxJFAvPSEQvF2g[o9zKGiHTmSy NV65W45KOjR5OECwPVg>
HeLa NYC3WmlUU2mwYYPlJGF{e2G7 NHXTWZdMcT1{MT62JOKyKDNwMDFOwG0h\m:{IHjDUnQy M1HUTFI1PzhyMEm4
HeLa MXfLbY5ie2ViQYPzZZk> NXr4RlVsU2l;MUSuOEDDuSB2Lk[g{txOKG[xcjDoR25VOw>? NGrRXZIzPDd6MEC5PC=>
NB4 MYTGeY5kfGmxbjDBd5NigQ>? NVPySY9COi53L{WvO{42NzFyIN88US=> M4fSNFI1KGh? NGDaOJdFVVOR NHHido1qdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi MkTLNlQ1QDR6N{C=
CD4+ CD25− T  NW\aUnlZTnWwY4Tpc44hSXO|YYm= NYXXfGF6OS93IN88US=> NHu3VHZz\WS3Y3XTJIdtd2KjbDDEUmEhdWW2aInsZZRqd25? MlPRNlQ1PzZ|NkC=
BV-173 NEjZNVBCeG:ydH;zbZMhSXO|YYm= NI\N[GwxNjJ3L{CuOU8xNjd3L{Gg{txO MVG0PE84Oi97NjDo NXfw[nlTyqCSQmO= NWDuPZU1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MoXFNlQ1OjN4MUO=
ML-1 NFL4fHJCeG:ydH;zbZMhSXO|YYm= Mnj5NE4zPS9yLkWvNE44PS9zIN88US=> MYm0PE84Oi97NjDo NXHHd2d5yqCSQmO= MonjbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MWqyOFQzOzZzMx?=
HL-60 M3rVUGFxd3C2b4Ppd{BCe3OjeR?= M4nG[lAvOjVxMD61M|AvPzVxMTFOwG0> NGXhcZY1QC95Mj:5OkBp MXxCpHBDWw>? M4O2W4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1L5ZlI1PDJ|NkGz
KG-1a NXe2XWtnSXCxcITvd4l{KEG|c3H5 MY[wMlI2NzBwNT:wMlc2NzFizszN MmrLOFgwPzJxOU[gbC=> MnjqxsBRSlN? MlzWbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy M1LzU|I1PDJ|NkGz
BV-173 MYPGeY5kfGmxbjDBd5NigQ>? MWqyOVAwPTBybl2= NIniW201QCCq NXO5[XhTyqCSQmO= MXHpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? NYT0NnM6OjR2MkO2NVM>
CEM M2W0ZmZ2dmO2aX;uJGF{e2G7 NFKxXWozPTBxNUCwcm0> M2DDdVQ5KGh? NF;ac5PDqFCEUx?= NXXyNollcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MYiyOFQzOzZzMx?=
HL-60 M3PvbWZ2dmO2aX;uJGF{e2G7 NYr4Z2FtOjVyL{WwNI5O NH3OT5A1QCCq NIDDXXjDqFCEUx?= M3r4NIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NUTlfnVvOjR2MkO2NVM>
ML-1 NX;kXlZQTnWwY4Tpc44hSXO|YYm= M2m0blI2OC93MEDuUS=> MWq0PEBp M1XSdeKhWEKV NFTEVllqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= NWXvPWd2OjR2MkO2NVM>
DLD-1 NELT[|BHfW6ldHnvckBCe3OjeR?= M1LyblI2OC93MEDuUS=> Mn3sOFghcA>? Mn2xxsBRSlN? MYLkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NX7FSJJmOjR2MkO2NVM>
HCT-116 M4faTGZ2dmO2aX;uJGF{e2G7 NEi0TGQzPTBxNUCwcm0> NEDBbWU1QCCq NULyfXRkyqCSQmO= MlPL[I8hdm:2IHnu[JVk\XNiZHXsZZlm\CCjbnSgd5V{fGGrbnXkJHJQWyCrbnPy[YF{\Q>? Mlf3NlQ1OjN4MUO=
U937-A/E-9/14/18  NUfmTpdISXCxcITvd4l{KEG|c3H5 M3j3WFAvODFxMD6xM|EwOTBizszN NYjxPGo1PDhiaB?= NF3QdlRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3PMUFI1OzByNEW2
HT29 M3v0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHIdHc4OiCq NHvJ[HpKSzVyPUG0NFDDuTF5OTFOwG0> M2npZlI1OTd{ME[x
SW48 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:yc5NGPzJiaB?= NUHGU4J5UUN3ME2xOU4zyrF4LkKg{txO MX[yOFE4OjB4MR?=
HCT116 M3\tR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPVV49NPzJiaB?= M3v1OWlEPTB;MT63xtExNjRizszN NXPRemFtOjRzN{KwOlE>
HepG2 NH3MepBHfW6ldHnvckBCe3OjeR?= NGT3U2sxNjVxMTFOwG0> NXXHR2k6OjRiaB?= NGn5eYxFVVOR NVW2OIhMfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NWXKbZBIOjRzNE[4O|Q>
LS174T NUDjZVJYTnWwY4Tpc44hSXO|YYm= MnnGNE42NzFizszN NV3xUJVZOjRiaB?= MVvEUXNQ NVvTbI5rdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> M2n3WlI1OTR4OEe0
HepG2 M1zyRmFxd3C2b4Ppd{BCe3OjeR?= NX;OfXcxOS9zMD:xNFAh|ryP M{POcVch\A>? MYfEUXNQ M{nPZolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NEDrXZkzPDF2Nki3OC=>
LS174T M1ewcWFxd3C2b4Ppd{BCe3OjeR?= M4XYS|EwOTBxMUCwJO69VQ>? MXq3JIQ> NULXRlRLTE2VTx?= MYPpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NIDnO|EzPDF2Nki3OC=>
QBC-939 MnjVRZBweHSxc3nzJGF{e2G7 NUHPU3FPOS9zMD:xNFAh|ryP NGXofFk4KGR? NH\xNoRFVVOR NUPhNJVkcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NIHtN4UzPDF2Nki3OC=>
U251 MXXBdI9xfG:|aYOgRZN{[Xl? NWHTS3NHOS9zMD:xNFAh|ryP NXjxOJFxPyCm NF7hSo9FVVOR NXThTVZZcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUSyOFE1Pjh5NB?=
HL-60 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[xJO69VQ>? NETw[mU1QCCq NV23WppMcW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= NX3LclhmOjRyMECzNlQ>
MDA‑MB‑453 NWOycWoxTnWwY4Tpc44hSXO|YYm= M3TNTVAvOi9zIN88US=> M4TIZ|czKGh? Mkm2Z4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NW\OZm9DOjN6NESyNlg>
HCC1569 MXHGeY5kfGmxbjDBd5NigQ>? M13wXVAvOi9zIN88US=> M4ntWVczKGh? NU[x[Yg2[2G3c3XzJJJmNWW6cILld5Nqd25ib3[gZ4xifWSrbtMgNeKh NV;5VIRiOjN6NESyNlg>
BT‑474 MVTGeY5kfGmxbjDBd5NigQ>? M{nZd|AvOi9zIN88US=> M4TlNVczKGh? MljRZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg MX:yN|g1PDJ{OB?=
AGS MkHuRZBweHSxc3nzJGF{e2G7 Mlf1OU8yOC9{MD:1NEDPxE1? NE[0Z|E1QMLiaNMg M1\CSGROW09? NGfpZ4VqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? NGC1fHgzOzV6Mke4OC=>
A549 NYPJ[ZY1SXCxcITvd4l{KEG|c3H5 NGrBblg2NzFyL{KwM|UxKM7:TR?= NXXUVHhxPDkEoHlCpC=> Ml\pSG1UVw>? MWfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NVfhPYs3OjN3OEK3PFQ>
AGS  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVy1M|ExNzJyL{WwJO69VQ>? M3nz[lQ5yqCqwrC= NGD5VmNFVVOR M3vTV4lv\HWlZYOgS|IwVSCyaHHz[UBienKnc4VCpC=> MlPuNlM2QDJ5OES=
Kasumi-1 NIHjUoZCeG:ydH;zbZMhSXO|YYm= NYe0dpcyOC53IN88US=> MYe0POKhcMLi NGjYVlVl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MVGyN|Q6OzN2OB?=
OCI-AML3 M3W3WGFxd3C2b4Ppd{BCe3OjeR?= M2PoR|IvPSEQvF2= MXS0POKhcMLi MV\k[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MYSyN|Q6OzN2OB?=
MV4-11 NXi1WnFWSXCxcITvd4l{KEG|c3H5 M{HIcVIvPSEQvF2= MlXSOFjDqGkEoB?= NF\WVFll\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> NYnocGtDOjN2OUOzOFg>
NK  NVTjVndNS3m2b4TvfIl1gSCDc4PhfS=> NGXWZ4oxNjB{LUKwJO69VQ>? M3Hoc|Uh\A>? MVTk[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm NX;MW3QyOjN|MkiwPFg>
NK  MkPTRZBweHSxc3nzJGF{e2G7 NV\YZ2oxOC5yMj2yNEDPxE1? M4XOUFUh\A>? NInXfHdl\WO{ZXHz[UBPUyClZXzsJJBzd2yrZnXyZZRqd25iYX7kJJZq[WKrbHn0fUBieyC2aHWgZ49v[2WwdILheIlwdiCrbnPy[YF{\WR? NYrOVW5bOjN|MkiwPFg>
NK  MkPYSpVv[3Srb36gRZN{[Xl? M1\oZVAvODFvMkCg{txO NYjiWmlMPSCm NXrtb3ly[2G3c3XzJIh6eG:vZYTofYxifGmxbjDv[kBPUyClZXzsd{BqdiCjIHTvd4XjiJO{ZYPwc45{\Q>? MnTENlM{OjhyOEi=
MOLT4/DNR NIfXc4tHfW6ldHnvckBCe3OjeR?= NYLuTZRpPSEQvF2= NXz6ToNEPCCm M2ja[5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NYKzbng{OjNyNkC1O|A>
Jurkat/DOX NXLKVW9WTnWwY4Tpc44hSXO|YYm= MV[1JO69VQ>? MXK0JIQ> M1fjN5Jm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v NG\5[4czOzB4MEW3NC=>
MOLT4/DNR MmLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;nT4c2KM7:TR?= M4rLPVQh\A>? MXLy[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 NGnTW20zOzB4MEW3NC=>
Jurkat/DOX NWDy[XBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjabI95PSEQvF2= MoGzOEBl MlfOdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= NGTocW8zOzB4MEW3NC=>
ccRCC  NH62[FdCeG:ydH;zbZMhSXO|YYm= M3XBPFAvODFvMUFOwG0> M4TQNlczKGh? NXXqZppPTE2VTx?= MmC1bIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>? MUOyNlgzPjR4Nx?=
TNBC  NYLvRW9LSXCxcITvd4l{KEG|c3H5 MX:wMlAyNTFyzszN MnrWO|IhcA>? MV3EUXNQ MUnoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v M{fqSVIzQDJ4NE[3
A498 M4P0e2Fxd3C2b4Ppd{BCe3OjeR?= NX\5fZlSOC5yMT2xNO69VQ>? M4C3bVczKGh? M4XlTGROW09? MojIbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MVOyNlgzPjR4Nx?=
KIJ265T NXjhdWo1SXCxcITvd4l{KEG|c3H5 MVewMlAyNTFyzszN MVS3NkBp M3i1NWROW09? MonhbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MluwNlI5OjZ2Nke=
MDA-231 NEHuNo9CeG:ydH;zbZMhSXO|YYm= Mn;0NE4xOS1zMN88US=> NFLBSVg4OiCq NFjmdIhFVVOR MXrpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MXyyNlgzPjR4Nx?=
BT-20 MUXBdI9xfG:|aYOgRZN{[Xl? MXSwMlAyNTFyzszN NUPFNW0zPzJiaB?= NE\HNmRFVVOR NHGy[mtqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv M1m5VVIzQDJ4NE[3
U937 NWi3bnozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoiyOU0zOCEQvF2= M3XHZ|I1NzR6L{eyJIg> MnnsbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXqyUllzOjJ5NkewNlE>
HL60 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Wzb|UuOjBizszN NYrsSIl{OjRxNEivO|IhcA>? MVPpcoR2[2W|IHGg[IVkemWjc3WgbY4h[2WubDD2bYFjcWyrdImgbY4h[SClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy NFHCdFEzOjd4N{CyNS=>
U937 MnvvRZBweHSxc3nzJGF{e2G7 NELI[4UyPSEQvF2= NW\Sd3FFOjRxNEivO|IhcA>? MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NH31RXczOjd4N{CyNS=>
HL60 NW\FO5dXSXCxcITvd4l{KEG|c3H5 MorINVUh|ryP MWiyOE81QC95MjDo NXnZPVUycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NXXyb4VwOjJ5NkewNlE>
LS411N  M324PWFxd3C2b4Ppd{BCe3OjeR?= MXiwMlUh|ryP M4rSeVczKGh? MVrpcoNz\WG|ZYOgSoF{KG2UTlGgcIV3\Wx? MlviNlI1PjF4OUW=
MDA-MB-231 MlTQRZBweHSxc3nzJGF{e2G7 NGTFd3YyOCEQvF2= NYOyXWlOPDhiaB?= MoLJdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWKyNVg5PzZ7Nx?=
MCF-7  MlXJRZBweHSxc3nzJGF{e2G7 M1PBSVExKM7:TR?= NIf6Z241QCCq MmLxdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnHDNlE5QDd4OUe=
A375 M3ezZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUGzc3YzOC53IN88US=> MWWxM|UwQCCm MXTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MnrENlE4QTZ4MkK=
SKMEL1 NY[0ZXJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6wMlUh|ryP Mni3NU82NzhiZB?= MVrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M37ZT|IyPzl4NkKy
SKMEL3 NVv3VVNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M331XlAvPSEQvF2= MmjqNU82NzhiZB?= NX7iZZpncW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= MV:yNVc6PjZ{Mh?=
SKMEL28 NWLvZVRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfhNE42KM7:TR?= NVHI[nZyOS93L{ig[C=> NVjxUmltcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= M{LFflIyPzl4NkKy
MeWo NHPMTmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\KWVExNjVizszN MVmxM|UwQCCm NIfwSmpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= Mlf6NlE4QTZ4MkK=
B16 MlHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHntUG0xNjVizszN MYSxM|UwQCCm NVHkW|ZmcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO= Mlj1NlE4QTZ4MkK=
Ly 1 M1i4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;YNVI1KGh? MYDJR|UxRTdwMzFOwG0> MUWyNVc4OjB2OR?=
Ly 7 NGfyZpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvuNlQhcA>? M1GzeGlEPTB;MUCuO{DPxE1? NHG5ZnMzOTd5MkC0PS=>
Su-DHL6 NXrxZ5N6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\kNlQhcA>? NFq4Tm1KSzVy78{eNlAh|ryP MYGyNVc4OjB2OR?=
Ly 10 NIH6WW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOyOEBp NVfXWYhSUUN3MP-8olIxKM7:TR?= MX2yNVc4OjB2OR?=
RIVA NE[0VpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTweWEzPCCq M3zxeWlEPTExvK6yNEDPxE1? MmHFNlE4PzJyNEm=
Su-DHL2 M2[1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVOyOEBp MXnJR|Ux97zgMkCg{txO NHuwVokzOTd5MkC0PS=>
Ly 1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjYVpE1QCCq MUXJR|UxRTBwM{Sg{txO NHftcGozOTd5MkC0PS=>
Ly 7 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrtUWhHPDhiaB?= MlTCTWM2OD1yLkCyOUDPxE1? Mm[yNlE4PzJyNEm=
Su-DHL6 NULHPXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37rb|Q5KGh? NFn3N|FKSzVy78{eNlAh|ryP NH3YXJAzOTd5MkC0PS=>
Ly 10 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLhfXA2PDhiaB?= MYDJR|UxRTFwODFOwG0> MlnPNlE4PzJyNEm=
RIVA NHm2Vo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PJR|Q5KGh? NH[zXFhKSzVy78{eNlAh|ryP MX2yNVc4OjB2OR?=
Su-DHL2 NF7adINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnLb3A1QCCq MUDJR|UxRTF5LkSg{txO NVzZXnhXOjF5N{KwOFk>
Ly 1 NV\We2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rub|czKGh? NGrSOVBKSzVyPUCuNFEh|ryP NXPDV45FOjF5N{KwOFk>
Ly 7 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\nUVczKGh? MmH3TWM2OD1yLkCxPEDPxE1? NF;sfZgzOTd5MkC0PS=>
Su-DHL6 NETneXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjS[no4OiCq MoH5TWM2OD1zLk[g{txO NHGzdGkzOTd5MkC0PS=>
Ly 10 M2HTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPHeG4xPzJiaB?= MXnJR|UxRTFwMjFOwG0> MVOyNVc4OjB2OR?=
RIVA NX7lO4R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\YWlczKGh? MWTJR|Ux97zgMkCg{txO M4fsT|IyPzd{MES5
Su-DHL2 MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O2dFczKGh? MYfJR|UxRTFzLkKg{txO MmTqNlE4PzJyNEm=

... Click to View More Cell Line Experimental Data

In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
+ Expand

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
+ Expand
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Formulation: Decitabine is dissolved in sterile PBS .
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
Synonyms Deoxycytidine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02839694 Recruiting Neoplasm Metastasis|Sarcoma|Neoplasms, Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7, 2016 Phase 1
NCT01479348 Enrolling by invitation Head and Neck Neoplasms|Lung Neoplasms|Urinary Bladder Neoplasms|Breast Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 28, 2011 Early Phase 1
NCT03041688 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|TP53 wt Allele|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) October 2017 Phase 1
NCT03009240 Not yet recruiting Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia City of Hope Medical Center|National Cancer Institute (NCI) June 2017 Phase 1
NCT02890329 Not yet recruiting Chimerism|Hematopoietic Cell Transplantation Recipient|Myelodysplastic Syndrome With Excess Blasts-1|Myelodysplastic Syndrome With Excess Blasts-2|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Adult Acute Myeloid Leukemia National Cancer Institute (NCI) April 2017 Phase 1
NCT02847000 Not yet recruiting Metastatic Pancreatic Adenocarcinoma Yogen Saunthararajah|Case Comprehensive Cancer Center March 2017 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID